Nuvation Bio Inc
NUVBHealthcare|Biotechnology|USA
$5.81
-0.30 (-4.91%)
Tangible Book
$0.89
Upcoming Data Readouts (5)
Mar 2027
Est. completion
P1P2Advanced Solid Tumor
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432n=466
Dec 2028
Est. completion
Jan 2029
Est. completion
P3Non Small Cell Lung Cancer
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
NCT06564324n=194
Dec 2029
Est. completion
Cancer
CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)
NCT04151342n=5,500
Aug 2030
Est. completion
P3Non-small Cell Lung Cancer (NSCLC)
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
NCT07154706n=180
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.